All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?

How challenging is it for you to achieve both clinically meaningful spleen volume reduction and constitutional symptom improvement in patients with cytopenic myelofibrosis?

Not difficult at all

0%

Somewhat difficult

0%

Difficult

33%

Very Difficult

66%

3 votes

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with myelofibrosis (MF)?

How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?

In this video, Mascarenhas discusses the analysis from the PERSIST-2 trial (NCT02055781), a randomized phase III study that investigated the safety and efficacy of oral pacritinib compared to the best available therapy to treat MF with thrombocytopenia.

 

Share: